Not a good buy right now for an impatient investor: trend is still bearish (SMA200 > SMA20 > SMA5) and price is below key pivot (2.768).
Oversold conditions (RSI6 ~28) and price sitting just above near-term support (S1 2.535) could spark a bounce, but it’s not a high-conviction entry without a clear reversal signal.
Insider selling is a major red flag (selling up ~2656.89% last month), outweighing the single bullish analyst note.
Price/Trend: Bearish structure with moving averages stacked negatively (SMA200 > SMA20 > SMA5), consistent with a downtrend.
Momentum: MACD histogram is above zero (0.0534) but positively contracting, suggesting bullish momentum is fading rather than accelerating.
RSI: RSI6 at ~28.4 indicates oversold/washed-out conditions (near-term rebound risk for shorts), but not a confirmed trend reversal.
Key levels: Pivot 2.768 (must reclaim to improve trend); immediate support S1 2.535 then S2 2.391; resistance R1 3.001 then R2 3.145.
Pattern-based forward bias: Similar-pattern stats imply a modest upside tilt (80% chance of +1.07% next day, +3.22% next week, +8.75% next month), but magnitude is small relative to typical biotech volatility.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment/positioning: Put/Call OI ratio 0.21 is call-heavy (bullish skew), but today’s option volume is 0, suggesting very thin/illiquid near-term options activity.
Volatility: Extremely elevated IV (30D IV ~792%; IV percentile ~94.6; IV rank ~77.4) implies the market is pricing a large move; options are likely expensive.
Open interest: Calls OI 663 vs puts OI 141 supports bullish positioning, but without volume confirmation, the signal is weaker.
Technical Summary
Sell
9
Buy
4
Positive Catalysts
Oversold technical setup near support (around 2.
can produce a fast mean-reversion bounce if sellers exhaust.
Neutral/Negative Catalysts
and roll over.
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: 0 (no YoY growth; remains effectively pre-revenue).
Profitability: Net income improved YoY to -$7.95M (22.93% improvement), and EPS improved to -0.21 (10.53% improvement) — losses narrowing, but still meaningfully negative.
Gross margin: reported drop to 0 (down -100% YoY), consistent with minimal/zero revenue base rather than operating leverage.
Takeaway: financials do not yet provide a fundamental “floor”; the stock remains driven by funding runway + trial data cadence.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Latest notable update (2026-01-05): H.C. Wainwright reiterated Buy with a $31 price target, citing encouraging interim efficacy signals and potential durability, with further data expected in 2026.
Trend/read-through: Bull case is event-driven (clinical data) with asymmetric upside if results hold; bear case is that this is a single-firm bullish view and the stock can keep sliding absent new catalysts.
Wall Street pros/cons view (based on provided data):
Pros: Strong optimism tied to interim oncology response/durability signals; very high PT implies perceived optionality.
Cons: Limited breadth of coverage shown here; near-term tape is weak and insider selling undermines confidence.
Wall Street analysts forecast GNLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GNLX is 22.5 USD with a low forecast of 16 USD and a high forecast of 31 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast GNLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GNLX is 22.5 USD with a low forecast of 16 USD and a high forecast of 31 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.350
Low
16
Averages
22.5
High
31
Current: 2.350
Low
16
Averages
22.5
High
31
H.C. Wainwright
H.C. Wainwright
maintain
$31
AI Analysis
2026-01-05
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$31
AI Analysis
2026-01-05
maintain
Reason
Genelux reported updated interim data showing IV Olvi-Vec plus platinum chemotherapy achieved a 33% overall response rate and 67% disease control rate in heavily pretreated platinum-relapsed/refractory lung cancer patients, outperforming historical response rates, with notable tumor shrinkage and signals of a dose-response effect at higher dosing, H.C. Wainwright tells investors in a research note. Early durability signals, including progression free survival extending to 12.1 months in one case despite single-cycle dosing and no maintenance therapy, suggest potential activity in overcoming platinum resistance, with further data expected in 2026, the firm says. H.C. Wainwright has a Buy rating and $31 price target on the shares.
Titan Partners
Boris Peaker
initiated
$20
2025-10-31
Reason
Titan Partners
Boris Peaker
Price Target
$20
2025-10-31
initiated
Reason
Titan Partners analyst Boris Peaker initiated coverage of Genelux with a Buy rating and $20 price target. The development-stage biotechnology company has an oncolytic viral therapy in a pivotal Phase 3 study, OnPrime, in ovarian cancer with data anticipated in the first half of 2026, notes the analyst, who says the firm's 12-18 month price target assumes positive results from OnPrime. Updates from ongoing studies in NSCLC and SCLC by year-end can act as additional catalysts, but are not factored into the firm's valuation, the analyst added.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GNLX
